Recorded fact · drug.label_indication
drug.label_indication for risankizumab-rzaa|psoriasis
One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact e14d6fb6 resolves to.
The record
| Fact id | e14d6fb68fe5bc6899b22479 |
|---|---|
| Entity | drug: risankizumab-rzaa|psoriasis |
| Field | drug.label_indication |
| Source | api.fda.gov |
| Read on | 2026-11-10T19:02:47.536Z |
| Source version | openfda-label-20260615 |
| Method | extract |
| Verification | verified |
| Licence | CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels |
| Edition | 2026-11, Merkle root 006ab9a329709cbe... |
The verifying quote
moderate-to-severe plaque psoriasis in adults and pediatric patients 6 years of age and older who are candidates for systemic therapy or phototherapy.
Shown with dashes as hyphens. SHA-256 of the exact stored quote: 9231bf0a0c8fba61e553a8540002a42ad2c6a04d046a0c75cf7c77ef304781e6.
The value
{
"ingredient": "Risankizumab-Rzaa",
"conditionId": "psoriasis",
"conditionName": "Psoriasis",
"matchedAlias": "psoriasis",
"context": "indication",
"brand": "Skyrizi",
"identifiedVia": "product_elements",
"extractor": 5,
"labelSetId": "7148c8eb-b39e-e20a-6494-a6df82392858",
"labelEffectiveTime": "20260615",
"labelsRead": 1,
"labelsNaming": 1,
"registryEditionRoot": "1b44e76f5da1a417",
"meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
}SHA-256 of the exact stored value: 4004f0c5b8fc9c9d2924108eecfe502abb68b5d1b04aad743e7351d21fabf80d.
This fact as data (JSON) · Check an answer against its receipt · Licence
Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.